Derma Sciences Beats Up on Analysts Yet Again

Before you go, we thought you'd like these...
Before you go close icon

Derma Sciences (NAS: DSCI) filed its 10-K on March 28. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Derma Sciences met expectations on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly. Non-GAAP loss per share grew. GAAP loss per share grew.


Gross margins grew, operating margins dropped, net margins shrank.

Revenue details
Derma Sciences booked revenue of $20.1 million. The four analysts polled by S&P Capital IQ expected revenue of $20.1 million on the same basis. GAAP reported sales were 22% higher than the prior-year quarter's $16.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.30. The four earnings estimates compiled by S&P Capital IQ averaged -$0.31 per share. Non-GAAP EPS were -$0.30 for Q4 compared to -$0.23 per share for the prior-year quarter. GAAP EPS were -$0.27 for Q4 against -$0.23 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 35.6%, 770 basis points better than the prior-year quarter. Operating margin was -20.6%, 670 basis points worse than the prior-year quarter. Net margin was -18.3%, 350 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $19.1 million. On the bottom line, the average EPS estimate is -$0.36.

Next year's average estimate for revenue is $83.1 million. The average EPS estimate is -$1.50.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with eight members out of 21 rating the stock outperform, and 13 members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), give Derma Sciences a green thumbs-up, and nine give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Derma Sciences is buy, with an average price target of $16.88.

Looking for alternatives to Derma Sciences? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.

The article Derma Sciences Beats Up on Analysts Yet Again originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners